Literature DB >> 26017508

Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.

L Grazzi1, S Usai.   

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin, a potent toxin produced by the anaerobic bacterium clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperhidrosis, is used for patients suffering from chronic migraine. In this study, a group of patients suffering from chronic migraine with medication overuse was treated with onabotulinum toxin A (Botox) to verify its efficacy for chronic migraine. The results confirmed the efficacy of onabotulinum toxin A (Botox) when used at the dosage of 155 UI according to the PREEMPT protocol. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of onabotulinum toxin A (Botox) and to assess its use in clinical practice, in particular in migraine field.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26017508     DOI: 10.1007/s10072-015-2140-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  13 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

2.  The International Classification of Headache Disorders, 3rd edition (beta version).

Authors: 
Journal:  Cephalalgia       Date:  2013-07       Impact factor: 6.292

Review 3.  Botulinum toxin type a for chronic migraine.

Authors:  Avi Ashkenazi
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

4.  Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?

Authors:  Eva Cernuda-Morollón; César Ramón; Davinia Larrosa; Rocío Alvarez; Nuria Riesco; Julio Pascual
Journal:  Cephalalgia       Date:  2014-11-27       Impact factor: 6.292

5.  OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Authors:  Stephen D Silberstein; Andrew M Blumenfeld; Roger K Cady; Ira M Turner; Richard B Lipton; Hans-Christoph Diener; Sheena K Aurora; Mai Sirimanne; Ronald E DeGryse; Catherine C Turkel; David W Dodick
Journal:  J Neurol Sci       Date:  2013-06-19       Impact factor: 3.181

6.  Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Authors:  Andrew Blumenfeld; Stephen D Silberstein; David W Dodick; Sheena K Aurora; Catherine C Turkel; William J Binder
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

Review 7.  Evidence for antinociceptive activity of botulinum toxin type A in pain management.

Authors:  K Roger Aoki
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

Review 8.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

9.  Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Authors:  Stephen D Silberstein; David W Dodick; Sheena K Aurora; Hans-Christoph Diener; Ronald E DeGryse; Richard B Lipton; Catherine C Turkel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-12-12       Impact factor: 10.154

10.  Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.

Authors:  John F Rothrock; Lisa M Bloudek; Timothy T Houle; Diane Andress-Rothrock; Sepideh F Varon
Journal:  Headache       Date:  2014-10-09       Impact factor: 5.887

View more
  11 in total

1.  Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment.

Authors:  Licia Grazzi
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

2.  The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.

Authors:  Marco Russo; Gian Camillo Manzoni; Arens Taga; Antonio Genovese; Licia Veronesi; Cesira Pasquarella; Giuliano Ezio Sansebastiano; Paola Torelli
Journal:  Neurol Sci       Date:  2016-04-05       Impact factor: 3.307

Review 3.  Chronic migraine: risk factors, mechanisms and treatment.

Authors:  Arne May; Laura H Schulte
Journal:  Nat Rev Neurol       Date:  2016-07-08       Impact factor: 42.937

4.  OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.

Authors:  Andrea Negro; Martina Curto; Luana Lionetto; Dorotea Crialesi; Paolo Martelletti
Journal:  Springerplus       Date:  2015-12-30

5.  Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.

Authors:  Michail Vikelis; Andreas A Argyriou; Emmanouil V Dermitzakis; Konstantinos C Spingos; Dimos D Mitsikostas
Journal:  J Headache Pain       Date:  2016-09-17       Impact factor: 7.277

Review 6.  Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.

Authors:  Piero Barbanti; Patrizia Ferroni
Journal:  J Pain Res       Date:  2017-09-29       Impact factor: 3.133

7.  Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.

Authors:  Brendan Davies; Charly Gaul; Paolo Martelletti; Juan Carlos García-Moncó; Stephanie Brown
Journal:  J Headache Pain       Date:  2017-09-06       Impact factor: 7.277

8.  OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.

Authors:  Danièle Ranoux; Gaelle Martiné; Gaëlle Espagne-Dubreuilh; Marlène Amilhaud-Bordier; François Caire; Laurent Magy
Journal:  J Headache Pain       Date:  2017-07-21       Impact factor: 7.277

9.  Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.

Authors:  I Aicua-Rapun; E Martínez-Velasco; A Rojo; A Hernando; M Ruiz; A Carreres; E Porqueres; S Herrero; F Iglesias; A L Guerrero
Journal:  J Headache Pain       Date:  2016-12-12       Impact factor: 7.277

10.  Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.

Authors:  Antonio Santoro; Andrea Fontana; Anna M Miscio; Michele M Zarrelli; Massimiliano Copetti; Maurizio A Leone
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.